TY - JOUR
T1 - Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: correlation with biologically-based risk stratification.
AU - Laurenti, Luca
AU - Innocenti, Idanna
AU - Autore, Francesco
AU - Ciolli, Stefania
AU - Mauro, Francesca Romana
AU - Mannina, Donato
AU - Del Poeta, Giovanni
AU - D’Arena, Giovanni
AU - Massaia, Massimo
AU - Coscia, Marta
AU - Molica, Stefano
AU - Pozzato, Gabriele
AU - Efremov, Dimitar G.
AU - Marasca, Roberto
AU - Galieni, Pietro
AU - Cuneo, Antonio
AU - Orlando, Sonia
AU - Piciocchi, Alfonso
AU - Boncompagni, Riccardo
AU - Vincelli, Donatella
AU - Liberati, Anna Marina
AU - Russo, Filomena
AU - Foa, Robin
PY - 2017
Y1 - 2017
N2 - First-line treatment for young/fit patients with chronic
lymphocytic leukemia (CLL) is the combination of flu-
d
arabine, cyclophosphamide and rituximab (FCR), which
has improved these patients’ progression-free survival
a
nd overall survival,
1
b
ut is poorly tolerated by elderly
patients or patients with comorbidities.
2
Such patients
have been historically treated with chlorambucil, which
is well tolerated but does not improve survival.
3
To
improve outcomes, chlorambucil has been combined
with anti-CD20 monoclonal antibodies. Three prospec-
tive studies
4-6
and one retrospective
7
one investigated the
combination of chlorambucil with rituximab (Chl-R) as
front-line treatment for elderly CLL patients or for
younger patients unsuitable for fludarabine-based thera-
pies. Overall response rates ranging from 66% to 84%
have been reported, with complete response rates of 8-
26% and progression-free survival from 16.3 to 34.7
months
AB - First-line treatment for young/fit patients with chronic
lymphocytic leukemia (CLL) is the combination of flu-
d
arabine, cyclophosphamide and rituximab (FCR), which
has improved these patients’ progression-free survival
a
nd overall survival,
1
b
ut is poorly tolerated by elderly
patients or patients with comorbidities.
2
Such patients
have been historically treated with chlorambucil, which
is well tolerated but does not improve survival.
3
To
improve outcomes, chlorambucil has been combined
with anti-CD20 monoclonal antibodies. Three prospec-
tive studies
4-6
and one retrospective
7
one investigated the
combination of chlorambucil with rituximab (Chl-R) as
front-line treatment for elderly CLL patients or for
younger patients unsuitable for fludarabine-based thera-
pies. Overall response rates ranging from 66% to 84%
have been reported, with complete response rates of 8-
26% and progression-free survival from 16.3 to 34.7
months
KW - CLL
KW - CLL
UR - http://hdl.handle.net/10807/106620
U2 - 10.3324/haematol.2016.156901
DO - 10.3324/haematol.2016.156901
M3 - Article
SN - 0390-6078
VL - 102
SP - 352
EP - 355
JO - Haematologica
JF - Haematologica
ER -